APA (7th ed.) Citation

Saura, C., Modi, S., Krop, I., Park, Y., Kim, S., Tamura, K., . . . Yamashita, T. (2024). Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01). Annals of Oncology, 35(3), 302. https://doi.org/10.1016/j.annonc.2023.12.001

Chicago Style (17th ed.) Citation

Saura, C., et al. "Trastuzumab Deruxtecan in Previously Treated Patients with HER2-positive Metastatic Breast Cancer: Updated Survival Results from a Phase II Trial (DESTINY-Breast01)." Annals of Oncology 35, no. 3 (2024): 302. https://doi.org/10.1016/j.annonc.2023.12.001.

MLA (9th ed.) Citation

Saura, C., et al. "Trastuzumab Deruxtecan in Previously Treated Patients with HER2-positive Metastatic Breast Cancer: Updated Survival Results from a Phase II Trial (DESTINY-Breast01)." Annals of Oncology, vol. 35, no. 3, 2024, p. 302, https://doi.org/10.1016/j.annonc.2023.12.001.